Earle W. Holmes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Earle W. Holmes has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Ali Keshavarzian
Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, USA
5 shared publications Edward W. Bermes
4 shared publicationsGordon J. Kinzler
Department of Urology, Loyola University Stritch School of Medicine, 2160 South First Avenue, Maywood, IL 60153, USA
4 shared publicationsRobert C. Flanigan
Department of Urology, Loyola University Medical Center, Maywood, Illinois
4 shared publicationsAli Banan
3 shared publicationsJean Garbincius
Clinical Laboratories, Loyola University Health System, Maywood, IL
3 shared publications
Latest Publications
- 1 December 2017
- Published by Elsevier in Clinical Biochemistry
- Vol. 50 (18) , 1025-1029
An interactive website for analytical method comparison and bias estimation
- 1 December 2017
- Published by Elsevier in Clinical Biochemistry
- Vol. 50 (18) , 1025-1029
An interactive website for analytical method comparison and bias estimation
- 1 November 2017
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 141 (11) , 1459-1460
Biotin Interference in Clinical Immunoassays: A Cause for Concern
Article Citation: Earle W. Holmes, Shanika Samarasinghe, Mary Ann Emanuele, and Farah Meah (2017) Biotin Interference in Clinical Immunoassays: A Cause for Concern. Archives of Pathology & Laboratory Medicine: November 2017, Vol. 141, No. 11, pp. 1459-1460. https://doi.org/10.5858/arpa.2017-0107-LE
- 1 November 2017
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 141 (11) , 1459-1460
Biotin Interference in Clinical Immunoassays: A Cause for Concern
Article Citation: Earle W. Holmes, Shanika Samarasinghe, Mary Ann Emanuele, and Farah Meah (2017) Biotin Interference in Clinical Immunoassays: A Cause for Concern. Archives of Pathology & Laboratory Medicine: November 2017, Vol. 141, No. 11, pp. 1459-1460. https://doi.org/10.5858/arpa.2017-0107-LE
- 1 August 2017
- Published by Elsevier in Endocrine Practice
- Vol. 23 (8) , 989-998
Biotin Interference with Routine Clinical Immunoassays: Understand the Causes and Mitigate the Risks
- 1 August 2017
- Published by Elsevier in Endocrine Practice
- Vol. 23 (8) , 989-998
Biotin Interference with Routine Clinical Immunoassays: Understand the Causes and Mitigate the Risks
- 1 June 2016
- Published by Wolters Kluwer Health in Point of Care: The Journal of Near-Patient Testing & Technology
- Vol. 15 (2) , 72-77
Investigation of Falsely Decreased Creatinine Results Observed From the Abbott I-STAT Point-of-Care Device in Use for Testing Specimens From Ambulatory Oncology Patients
The goals of this study were to assess the use of the I-STAT for blood creatinine measurement in oncology patients and to determine whether chemotherapy or other factors contributed to the discrepant point-of-care creatinine test results observed in specimens from patients in ambulatory oncology settings. Our studies led us to consider other possible causes of observed discrepancies beyond the effects of chemotherapeutic drugs, including lot-to-lot variation in I-STAT reagent cartridges.
- 1 June 2016
- Published by Wolters Kluwer Health in Point of Care: The Journal of Near-Patient Testing & Technology
- Vol. 15 (2) , 72-77
Investigation of Falsely Decreased Creatinine Results Observed From the Abbott I-STAT Point-of-Care Device in Use for Testing Specimens From Ambulatory Oncology Patients
The goals of this study were to assess the use of the I-STAT for blood creatinine measurement in oncology patients and to determine whether chemotherapy or other factors contributed to the discrepant point-of-care creatinine test results observed in specimens from patients in ambulatory oncology settings. Our studies led us to consider other possible causes of observed discrepancies beyond the effects of chemotherapeutic drugs, including lot-to-lot variation in I-STAT reagent cartridges.
- Open Access
- 1 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (S1) , 833.3
Synthetic melanin polymers with antithrombotic activity (833.3)
I evaluated the anticoagulant properties of a family of novel water soluble melanin polymers (Mels) synthesized by a patented process (12/809,369). Mels were screened for activity in standard assays for the measurement of the PT, the aPTT and the TT. Active Mels were further investigated by the evaluation of the kinetics of fibrin polymerization and the re‐polymerization of fibrinopeptides, and for the direct inhibition of factors Xa and thrombin. Ten of the Mels prolonged the aPTT and the TT by more than 2‐ fold (aPTT: mean, 3.7‐fold, range, 2.1‐6.7; TT: mean, 8‐fold, range, 2.1‐15). Mels C1, C12, EM and CAM (2.5 to 41mcg/mL) caused dose‐dependent delays in the onset, rate, and extent of thrombin‐mediated fibrinogenesis in the presence and absence of Ca++. Mels C1 and C12 inhibited the re‐polymerization of fibrinopeptides at high doses, but increased the rate and extent of re‐polymerization at low doses. Mels minimally inhibited factor Xa activity in a chromogenic assay, whereas Mels C1, EM, and C12 inhibited the hydrolysis of a chromogenic thrombin substrate by 49%, 39%, and 28%, respectively. Mels inhibit the common pathway of coagulation by multiple mechanisms. These activities, in conjunction with the high chemical reactivity of the intermediates that are generated during Mel synthesis may provide a new approach to the incorporation anti‐thrombotic properties into biomaterials.
- 1 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (S1) , 833.3
Open AccessSynthetic melanin polymers with antithrombotic activity (833.3)
I evaluated the anticoagulant properties of a family of novel water soluble melanin polymers (Mels) synthesized by a patented process (12/809,369). Mels were screened for activity in standard assays for the measurement of the PT, the aPTT and the TT. Active Mels were further investigated by the evaluation of the kinetics of fibrin polymerization and the re‐polymerization of fibrinopeptides, and for the direct inhibition of factors Xa and thrombin. Ten of the Mels prolonged the aPTT and the TT by more than 2‐ fold (aPTT: mean, 3.7‐fold, range, 2.1‐6.7; TT: mean, 8‐fold, range, 2.1‐15). Mels C1, C12, EM and CAM (2.5 to 41mcg/mL) caused dose‐dependent delays in the onset, rate, and extent of thrombin‐mediated fibrinogenesis in the presence and absence of Ca++. Mels C1 and C12 inhibited the re‐polymerization of fibrinopeptides at high doses, but increased the rate and extent of re‐polymerization at low doses. Mels minimally inhibited factor Xa activity in a chromogenic assay, whereas Mels C1, EM, and C12 inhibited the hydrolysis of a chromogenic thrombin substrate by 49%, 39%, and 28%, respectively. Mels inhibit the common pathway of coagulation by multiple mechanisms. These activities, in conjunction with the high chemical reactivity of the intermediates that are generated during Mel synthesis may provide a new approach to the incorporation anti‐thrombotic properties into biomaterials.
- Open Access
- 1 October 2013
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 140 (4) , 550-560
Analytical Variability Among Methods for the Measurement of 25-Hydroxyvitamin D
Objectives: To compare total 25-hydroxyvitamin D [25(OH) D] results measured by 3 direct immunoassays, including the previous version of the DiaSorin Liaison2 assay and the current versions of the Siemens Centaur2 and the Abbott Architect assays, with results measured in serum extracts by liquid chromatography/tandem mass spectrometry (LC/MS) and radioimmunoassay (RIA). Methods: Our study sample consisted of 163 consecutive clinical specimens submitted to our laboratory for 25(OH)D testing. Results: Regression and bias analyses of the data revealed that results measured by the 3 direct immunoassay methods had high degrees of random variability and bias relative to the results determined by LC/MS and RIA. The relative biases between results measured by the direct assays and the comparison methods exceeded a recommended criterion for the total allowable error of a 25(OH)D test in as many as 48% of our clinical specimens. Of the subjects in our study sample, 33, 37, 30, 45, and 71 were classified as vitamin D deficient based on results determined by LC/MS, RIA, Liaison2, Architect, and Centaur2, respectively. Conclusions: Intermethod variability in 25(OH)D assays continues to limit our progress toward the establishment of reference values for 25(OH)D in health and our efforts to gain a better understanding of the role of vitamin D insufficiency as a risk factor for disease.
- 1 October 2013
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 140 (4) , 550-560
Open AccessAnalytical Variability Among Methods for the Measurement of 25-Hydroxyvitamin D
Objectives: To compare total 25-hydroxyvitamin D [25(OH) D] results measured by 3 direct immunoassays, including the previous version of the DiaSorin Liaison2 assay and the current versions of the Siemens Centaur2 and the Abbott Architect assays, with results measured in serum extracts by liquid chromatography/tandem mass spectrometry (LC/MS) and radioimmunoassay (RIA). Methods: Our study sample consisted of 163 consecutive clinical specimens submitted to our laboratory for 25(OH)D testing. Results: Regression and bias analyses of the data revealed that results measured by the 3 direct immunoassay methods had high degrees of random variability and bias relative to the results determined by LC/MS and RIA. The relative biases between results measured by the direct assays and the comparison methods exceeded a recommended criterion for the total allowable error of a 25(OH)D test in as many as 48% of our clinical specimens. Of the subjects in our study sample, 33, 37, 30, 45, and 71 were classified as vitamin D deficient based on results determined by LC/MS, RIA, Liaison2, Architect, and Centaur2, respectively. Conclusions: Intermethod variability in 25(OH)D assays continues to limit our progress toward the establishment of reference values for 25(OH)D in health and our efforts to gain a better understanding of the role of vitamin D insufficiency as a risk factor for disease.
- 1 February 2013
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 304 (3) , H444-H454
Chronic fluoxetine reduces autonomic control of cardiac rhythms in rats with congestive heart failure
Up to 40% of patients with heart failure develop depression, and depression is an independent risk factor for cardiovascular mortality in this patient population. Consequently, increasing numbers of patients with heart failure are treated with antidepressants. Selective serotonin reuptake inhibitors are typically the antidepressant of choice since this drug class has limited cardiovascular toxicity. However, little is known about the effects of selective serotonin reuptake inhibitors on autonomic cardiac regulation in congestive heart failure (CHF). Here, indexes of cardiac autonomic control were evaluated before and during chronic fluoxetine (FLX) treatment (20 mg·kg−1·day−1, 5 wk) in rats that developed CHF after coronary artery ligation. FLX reduced the low-frequency (LF) component of heart rate variability (HRV; P < 0.01) as well as the sympathetic contribution to LF HRV ( P < 0.01) in both CHF and sham-operated rats. Both FLX and CHF reduced high-frequency HRV ( P < 0.01). Spontaneous baroreflex gain was decreased in CHF rats 8 wk after ligation ( P < 0.01). Cross-spectral coherence between the interbeat interval and mean arterial pressure was reduced in the LF domain 3 wk after ligation in CHF rats ( P < 0.01) and was further reduced after chronic FLX treatment ( P < 0.01). Plasma catecholamines and LF blood pressure variability were not affected by FLX. Chronotropic responses to both efferent vagal nerve stimulation and isoproterenol administration were reduced in CHF rats and by FLX ( P < 0.01), whereas inotropic responses to isoproterenol were reduced only in CHF rats ( P < 0.01). These data indicate that chronic FLX reduces the responsiveness to autonomic output controlling cardiac rhythm and may further compromise autonomic regulation of cardiac function in CHF.
- 1 February 2013
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 304 (3) , H444-H454
Chronic fluoxetine reduces autonomic control of cardiac rhythms in rats with congestive heart failure
Up to 40% of patients with heart failure develop depression, and depression is an independent risk factor for cardiovascular mortality in this patient population. Consequently, increasing numbers of patients with heart failure are treated with antidepressants. Selective serotonin reuptake inhibitors are typically the antidepressant of choice since this drug class has limited cardiovascular toxicity. However, little is known about the effects of selective serotonin reuptake inhibitors on autonomic cardiac regulation in congestive heart failure (CHF). Here, indexes of cardiac autonomic control were evaluated before and during chronic fluoxetine (FLX) treatment (20 mg·kg−1·day−1, 5 wk) in rats that developed CHF after coronary artery ligation. FLX reduced the low-frequency (LF) component of heart rate variability (HRV; P < 0.01) as well as the sympathetic contribution to LF HRV ( P < 0.01) in both CHF and sham-operated rats. Both FLX and CHF reduced high-frequency HRV ( P < 0.01). Spontaneous baroreflex gain was decreased in CHF rats 8 wk after ligation ( P < 0.01). Cross-spectral coherence between the interbeat interval and mean arterial pressure was reduced in the LF domain 3 wk after ligation in CHF rats ( P < 0.01) and was further reduced after chronic FLX treatment ( P < 0.01). Plasma catecholamines and LF blood pressure variability were not affected by FLX. Chronotropic responses to both efferent vagal nerve stimulation and isoproterenol administration were reduced in CHF rats and by FLX ( P < 0.01), whereas inotropic responses to isoproterenol were reduced only in CHF rats ( P < 0.01). These data indicate that chronic FLX reduces the responsiveness to autonomic output controlling cardiac rhythm and may further compromise autonomic regulation of cardiac function in CHF.
- Open Access
- 1 November 2012
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 138 (suppl 2) , A153
Lung Cancer: Can Pathologic Features Predict Molecular Alterations?
Lung cancer is the second most common cancer in the United States. Since therapeutic regimens target specific mutations, molecular testing has become routine practice. Molecular analysis is expensive and poses a burden on rising health care costs. The present study was undertaken to see if pathologic features are predictive of molecular alterations in lung cancers. A retrospective search of the pathology archives at Loyola University Medical Center was performed from June 2006 to July 2012. Data were recorded, including age, sex, tumor grade, and molecular profile. Morphologic patterns and tumor grade were reviewed for all mutation-positive cases by 2 board-certified pathologists. There were a total of 125 cases (nonsquamous carcinomas), including 19 cytology cases. There were 94 adenocarcinomas and 8 adenosquamous and 23 poorly differentiated carcinomas. Of 125 cases, 30 had a positive mutation: EGFR, 11; KRAS, 17; and EML4-ALK, 2. Although EGFR-positive cases had a female predominance, it was not statistically significant; KRAS showed a lower average age (61 vs 67 years [control]; P = .013); no other trend was seen related to age or sex. EGFR-positive cases were more well-differentiated compared with negative controls (38% vs 9% of cases). EGFR and KRAS cases did not exhibit a trend regarding specific histologic patterns. The 2 EML4-ALK-positive cases were well-differentiated mucinous adenocarcinomas. The data reiterate that EGFR-positive cases tend to show well-differentiated morphologic features. However, KRAS-positive cases seem to have no unique defining characteristics except for a slightly younger patient presentation. Even though our 2 EML4-ALK-positive cases showed mucinous adenocarcinoma, the number is too small to draw any conclusion. Most significant, the results show that histologic pattern analysis falls short of predicting molecular alterations and, hence, cannot be used as a cost-saving measure.
- 1 November 2012
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 138 (suppl 2) , A153
Open AccessLung Cancer: Can Pathologic Features Predict Molecular Alterations?
Lung cancer is the second most common cancer in the United States. Since therapeutic regimens target specific mutations, molecular testing has become routine practice. Molecular analysis is expensive and poses a burden on rising health care costs. The present study was undertaken to see if pathologic features are predictive of molecular alterations in lung cancers. A retrospective search of the pathology archives at Loyola University Medical Center was performed from June 2006 to July 2012. Data were recorded, including age, sex, tumor grade, and molecular profile. Morphologic patterns and tumor grade were reviewed for all mutation-positive cases by 2 board-certified pathologists. There were a total of 125 cases (nonsquamous carcinomas), including 19 cytology cases. There were 94 adenocarcinomas and 8 adenosquamous and 23 poorly differentiated carcinomas. Of 125 cases, 30 had a positive mutation: EGFR, 11; KRAS, 17; and EML4-ALK, 2. Although EGFR-positive cases had a female predominance, it was not statistically significant; KRAS showed a lower average age (61 vs 67 years [control]; P = .013); no other trend was seen related to age or sex. EGFR-positive cases were more well-differentiated compared with negative controls (38% vs 9% of cases). EGFR and KRAS cases did not exhibit a trend regarding specific histologic patterns. The 2 EML4-ALK-positive cases were well-differentiated mucinous adenocarcinomas. The data reiterate that EGFR-positive cases tend to show well-differentiated morphologic features. However, KRAS-positive cases seem to have no unique defining characteristics except for a slightly younger patient presentation. Even though our 2 EML4-ALK-positive cases showed mucinous adenocarcinoma, the number is too small to draw any conclusion. Most significant, the results show that histologic pattern analysis falls short of predicting molecular alterations and, hence, cannot be used as a cost-saving measure.
- Open Access
- 4 October 2012
- Published by Wiley in Pathology Research International
- Vol. 2012, 1-8
The Prognostic Value of Lymph Node Cross-Sectional Cancer Area in Node-Positive Breast Cancer: A Comparison with N Stage and Lymph Node Ratio
The number of positive axillary lymph nodes (LNs) is the only node-related factor for prognostic evaluation of breast cancer recognized by AJCC (TNM staging). However, N staging may not completely reflect LN tumor involvement due to the erroneous count of LNs in the presence of matted LNs and different tumor volume in LNs. Additionally, the positive/total LN ratio (LNR) has been shown to outperform N staging in survival prediction. In our study, to better quantify the tumor involvement of axillary LNs, we measured the cross-sectional cancer area (CSCA) of the positive LNs in 292 breast cancer patients diagnosed between 1998 and 2000 in our institution and compared its prognostic value to that of number of positive LNs (metLN)/N stage and LNR. Statistical analyses of these three LN-related factors were performed by Kaplan-Meier method and multivariate Cox's regression model. Patients were divided into three groups based on the different LN CSCA (500 mm2), or LNR (0.65), or N stage (N1–N3). Multivariate analysis demonstrated LNR was the most significant LN-related survival predictor with hazard ratio (HR) 25.0 (), compared to the metLN (HR 0.09, ) and CSCA (HR 2.24, ).
- 4 October 2012
- Published by Wiley in Pathology Research International
- Vol. 2012, 1-8
Open AccessThe Prognostic Value of Lymph Node Cross-Sectional Cancer Area in Node-Positive Breast Cancer: A Comparison with N Stage and Lymph Node Ratio
The number of positive axillary lymph nodes (LNs) is the only node-related factor for prognostic evaluation of breast cancer recognized by AJCC (TNM staging). However, N staging may not completely reflect LN tumor involvement due to the erroneous count of LNs in the presence of matted LNs and different tumor volume in LNs. Additionally, the positive/total LN ratio (LNR) has been shown to outperform N staging in survival prediction. In our study, to better quantify the tumor involvement of axillary LNs, we measured the cross-sectional cancer area (CSCA) of the positive LNs in 292 breast cancer patients diagnosed between 1998 and 2000 in our institution and compared its prognostic value to that of number of positive LNs (metLN)/N stage and LNR. Statistical analyses of these three LN-related factors were performed by Kaplan-Meier method and multivariate Cox's regression model. Patients were divided into three groups based on the different LN CSCA (500 mm2), or LNR (0.65), or N stage (N1–N3). Multivariate analysis demonstrated LNR was the most significant LN-related survival predictor with hazard ratio (HR) 25.0 (), compared to the metLN (HR 0.09, ) and CSCA (HR 2.24, ).
- 1 November 2011
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (23) , 2355-2356
Non-linear analytical recovery in the DiaSorin Liaison immunoassay for 25-hydroxy vitamin D
- 1 November 2011
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (23) , 2355-2356
Non-linear analytical recovery in the DiaSorin Liaison immunoassay for 25-hydroxy vitamin D